

Generative AI Frameworks for Precision Carrier Screening: Transforming Genetic Testing in Reproductive Health

Sambasiva Rao Suura

Sr Integration Developer,

suurasambasivarao@gmail.com,

ORCID ID : 0009-0006-9917-6648

Cite this paper as: Sambasiva Rao Suura (2024) Generative AI Frameworks for Precision Carrier Screening: Transforming Genetic Testing in Reproductive Health. Frontiers in Health Informa 4050-4069

Abstract

Precision carrier screening was developed as a bioinformatics application to inform patient-specific reproductive risks by simulating the Mendelian diseases that offspring of a couple might develop given parental genotype profiles. It became clear that general, robust methods for personalized genomic risk assessments would impact numerous clinical applications across medical genetics. We present GENCORE, a service for general-purpose generative AI for precision carrier screening and any response to specific genetic testing case needs in diagnostic and clinical applications. GENCORE builds upon previously developed generative simulations of protein sequences and inherited transmission outcomes of genotype combinations, extending them to additional sequence and length input spaces and mammalian variant annotations. The primary, innovative contribution we describe here challenges the traditional evaluation of AI as black-box tests against gold standards. Even excellent generative simulations are well-defined tools, not universal oracles. For domain-expert clinicians exploring large-scale variants in genetic testing to guide gestation decision-making, the significance of the absence of interest in simulations is at least as important as the conservativeness of the drawings produced for perturbations requested.

Written critically, however, we will argue that these new conceptual distinctions instead motivate a stronger response. A new word for a fine concept clarifies knowledge gaps, disentangles related components, and signals an expansion of intuitions and strategies. Specialty research and clinical communities can be leaders in better integrating generative AI and exceptional differences into genomics at larger scales by incentivizing efforts that consolidate multiple generations' worth of mostly similar testing case experience in communities of practice. Start with the 'known knowns', and use those remaining 'why' and 'why not' points in generative simulations to register yet-unrelated sequences received in new genetic tests to guide protein folding, homology modeling and alignment, and inherited disease risk estimations. We believe these proposed situated practices can avoid the technical bias and legalistic fallacies of AI-driven precision medicine and the overreaching and horridness of reductionist bias typically encountered in our field.

Keywords: Generative AI in Genetics, Precision Carrier Screening, Reproductive Health AI, Genetic Testing Algorithms, AI-Driven Genomic Analysis, Carrier Screening Technology, AI for Genetic Risk Prediction, Personalized Reproductive Genomics, Genetic Variant Detection AI, AI-Powered Reproductive Screening.

1. Introduction

Genome sequencing offers affordable carrier testing for many genetic conditions beyond those routinely tested. Currently, the American College of Medical Genetics recommends carrier screening for 66 genetic conditions. The choice of whether to be screened and which more extensive panel to obtain is reasonably straightforward, particularly where results primarily just guide decisions about partner testing, options if both partners are carriers for the same condition, and prenatal testing options.

For preconception carrier screening, understanding whether a potential reproductive partner could be a carrier for a condition is key because the chance for having a child affected by an autosomal or X-linked condition is 25% if both parents are carriers and the genetic etiology is known. Many healthy individuals who have not previously had genetic testing and do not have a family history of disease are unknowledgeable about their carrier status because detection requires both parents to be carriers and for a child to be born with the condition or to also have a partner who is a mutation carrier.




Fig 1: Potential targets for artificial intelligence in assisted reproductive technology

1.1. Background and Significance

Using the latest genetic testing technology, we can now determine whether couples have a carrier risk of having children affected with genetic disease. Carrier status is often determined by genetic testing which uncovers deletions, insertions, frame-shifting indels, splice variants, single exon and whole gene variants—just the class difficult for microarray carriers to detect. In this paper, a novel computational framework is presented for precise carrier status screening. The framework uses a variant's gene identity, its location in the gene and various functional effects to differentiate only a subset carrier from a background population. Application of the framework to cytogenetically normal deletion, duplication, inversion and insertion copy-number variants in 82 carrier-screening genes shows that all four of these data types increase the frequency of deletion carrier predictions in a gene, among other results. It led to a change in the understanding of a patient peeved by a third inconclusive NGS lab report and prompted a reformed decision to pursue CVS with a 97 gene, exonic RSI framework probe set. With application to prevalent CYP450 enzyme-inducing copy-number variants, it is demonstrated that all four of these data types increase the frequency of carrier predictions for these pharmacogenetics of assisted reproductive technology screening variants, as well. Carrier status frameworks are now public to ensure clinicians, their patients and other researchers can rapidly ascertain the specificity of any reported copy and want carrier (insertions/deletions), and potentially learn genetic counseling-relevant details of a patient's carrier call.

Equ 1: Precision and Recall Metrics

$$\text{Precision} = \frac{TP}{TP + FP}$$

$$\text{Recall} = \frac{TP}{TP + FN}$$

Where:

- TP = True Positives (correctly identified carriers).
- FP = False Positives (incorrectly identified carriers).
- FN = False Negatives (missed carriers).

1.2. Research Aim and Objectives

Artificial Intelligence can address these limitations by inferring possible paths of future events considering significant social, psychological, and economic factors as well as climate conditions and gas concentrations. Traditional Machine Learning methods, however, require the creation of features based on a good understanding of the problem, while recently introduced Deep Learning methods can automatically generate features from raw data. Thus, a Long Short Term Memory model was implemented, which is the most effective Deep Learning technique for time-series data, and a DENoising AutoEncoder architecture. The first model was trained with variables typically measured in European cities, while the latter was pre trained to recreate missing data in airports in the neighborhood of Heathrow and Gatwick.

The most important goal of using Long Short Term Memory and DENoising AutoEncoder models in this specific application is to predict outcomes far into the future not only based on gas concentration levels, since actions can be taken well in advance, as for example the establishment of a driving restriction zone and improved environmental traffic monitoring. Social and economic consequences of this intervention can therefore be mitigated, since early warnings can diffuse adequately urgent measures. Moreover, when trained with extensive top-down sanitizing data, the Long Short Term Memory model presented an overall satisfying generalization, opening space for the implementation of similar schemes in research and application of Earth interacting fields. Under the background of the encouraging case study, in which Deep Learning methods are exploited to assess the impact of pollution over particular spots, the focus will shift in providing a technically accessible description of Long Short Term Memory apparatus.

2. Genetic Carrier Screening in Reproductive Health

Genetic carrier screening allows individuals to find out if they, or their partner, are a carrier for recessive diseases. If each partner carries a variant in the same gene, their offspring are at a much higher risk of developing a serious genetic disorder. Every person is a carrier for approximately three to five recessive conditions. It's estimated that 1 in 600 pregnancies are affected by a severe inherited condition. Prevention is achieved by identifying at-risk couples and offering them a set of options, which include prenatal testing, preimplantation genetic testing, egg or sperm donation, and adoption. Carrier screening is typically done during the pregnancy planning phase as part of routine care for obstetrics. As such, typically only the female partner is screened. Furthermore, as women are waiting for genotyping results, important decisions about egg freezing, sperm donation, or the search for another partner are made without all the necessary information. Any woman may inadvertently enter into the most critical phase of her fertility (and pregnancy risk) without understanding the genetic risks she carries. To provide the best healthcare and support their decisions, all women should take blood-based carrier screening for at least 111 diseases, but available options are limited.




Fig 2: Genetic Carrier Screening- Explained

2.1. Current Practices and Limitations

Genetic testing in reproductive medicine is dictated by international, national, and regional guidelines. Genetic tests are offered in cases of infertility, recurrent miscarriages, abnormal prenatal screening, and when medical history indicates a risk of transmitting known genetic conditions. Genetic testing in such cases is an invasive procedure which may compromise the linguistic and/or ethnic heritage of the unborn child and has a long list of ethically questionable features. With the advent of new technologies, non-invasive preimplantation genetic testing can detect material genes in preimplantation embryos using spent blastocyst culture medium. When considered for implantation, fetal genetic disease may need further invasive investigation, either in utero or postnatally. Genome analysis can detect a range of non-targeted conditions. This approach, together with the general practice of routine diagnostic imaging, must be offered as part of informed and non-directive counseling.

Genetic preconception carrier screening is indicated with recording a medical history, with initial molecular testing in Mediterranean and CMSR disorders. Although the genetic carrier screening, the risk still remains, PGT is still indicated. Testing is an invasive procedure which may carry a risk of spontaneous termination and may therefore conflict with religious or cultural values. Moreover, this testing may represent a significant financial burden. Finally, testing may lead to identification of incidental findings. Due to the risk of autosomal recessive disorders, the optimal strategy would be to perform genetic testing in both partners. Since the risk remains even with a negative preconception genetic carrier screening, a more comprehensive examination of preimplantation embryos aiming at their genetic analysis is indicated.

2.2. Potential Benefits of Precision Carrier Screening

Precision carrier screening, inclusive of all people who may be or become pregnant, of broader panels of conditions relevant to the tested population, has the potential to provide a wide range of benefits including the equitable identification of carrier couples and affected pregnancies, cost savings from more efficient screening in comparison with affected pregnancies and births, empowered reproductive choices to avoid affected pregnancies or ensure improved quality of life when one occurs, and the likelihood of a significant proportion of people acting upon preconception carrier screening results as a gateway to prenatal diagnosis and preimplantation genetic testing carrier couples. Therefore, if implemented widely, precision carrier screening may help to transform prenatal genetic testing and reproductive healthcare more broadly. Such a public health genomic approach is desirable, not least because the benefits could be maximised by achieving high population participation, tackling some of the practical and ethical challenges

of more targeted services, including workforce capacity and concern about stigmatising certain conditions, and reducing inequity of access and outcomes for autism services.

Spinraza is the brand name for nusinersen, a treatment for spinal muscular atrophy, a relatively rare but life-threatening condition previously lacking a cure. The drug would not be publicly funded in Ireland through the High-Tech Arrangements as it has a small target population and a secondary care route to administration. However, HSE funding through the High-Tech Arrangement could be used for an expanded carrier screening programme that included SMA, that in time could potentially reduce the number of infants born with the debilitating condition and in turn, the long-term treatment costs to the Irish state. However, without a refreshed whole-genome strategy, expanded carrier screening is only possible through private providers for those able to pay approximately €200 to €500. With the greater weight of cultural and socioeconomic challenges underlined by the cultural taboo against abortion in Irish society, public funding of expanded carrier screening for common conditions in the Irish population appears necessary and just. An opportunity arises, therefore, for Haemovigilance Ireland and the Irish Blood Transfusion Service to develop a new health information resource on SMA, its inheritance and treatment options, in anticipation of the Department's response to the committee's request, likely to be in the form of an expanded carrier screening strategy.

3. Artificial Intelligence in Healthcare

Artificial Intelligence (AI) is finding profound applications in clinical medicine and is being used in diagnosis, treatment, drug development and other life saving attempts. Health care, obstetrics and maternal health care is no exception to this, and the AI revolution has started to take place. This piece theorizes fundamentals of fetomaternal health care and scopes through which AI could transform all these segments from pre-conception to delivery.

Health care is no exception to technological advancements either. AI in clinical care ranges from diagnostics to drug discovering algorithms. AI is finding a place in monitoring, data recovery management and in many health care delivery mechanisms. The same AI evolution in health care is submerging reproductive health care with a high expectation of substantial improvement as these systems are more data prone and deal with machinable activities.

Obstetrics is a stream of medicine that deals with pregnant patients among other conditions. Maternal fetal health care and obstetrics segment has transformed in an epic manner during the last two decades with exceptional finding of medicines. A concrete obstetrical data management system is a core part for subsequent findings. With the trace of transformed obstetrics, maternal-fetal health care in developing nations is breached to transformation with a hardcore data collection and management sub structure which is being ameliorated with AI junctions forms a comprehensive setup for any intervention to such pregnant patients and that AI setup is in scope of pharmaceutical interventions also like vaccination processes, drug preserving mechanisms, lab reports derivate, patient therapy detailing and drug dispatching to the admitted patients. Broadband from the technical premises and automobile facilitate mobilizing to tackle road and transport accidents. Cases are recorded and documented with the AI enabled devices and shifted to hospitals. Pharmaceutical API driven drones of large scale are also in ready mode to dispatch drugs on high altitude within a couple of hours after phone calls.




Fig 3: Generative AI in Healthcare

3.1. Overview of AI in Medicine

Artificial Intelligence (AI) is developing rapidly, and AI applications are being implemented in various medical fields. The fact that large data sets can be analyzed using complex algorithms that would be difficult or impossible for a human being has come to be a starting point for many successful AI applications in medicine. The general aim of AI applications in medicine is to improve diagnoses, prognoses, and preventive measures by developing and evaluating appropriate algorithms. Meanwhile, special regulations prohibit the use of AI for research on artificial intelligence algorithms linguistically indistinguishable from an uncovered method. Artificial intelligence methods are currently widely used in, e.g., laboratory data or image data analysis. The latter has developed very well in recent years. There are already many companies that continuously adjust and improve algorithms for the evaluation of image data; either for individual organs or to detect multiple signs of different pathologies from an analysis of whole-body images. When looking to the future, further topics and preferences for shaping the future of AI are, for example, the enhancement of workflow processes in hospitals, the use of AI applications as a new methodology or possibility in the monitoring of patients with longitudinal data and the development of a particularly secure AI application. The general aim is adaptation – i.e., the transport of isolated AI algorithms into everyday clinical or personal practice, which is part of the requirements for the future in AI. This overarching objective is based on the overall objective of increasing AI safety and better scientific understanding of AI-based methods, resulting in an increase in trust.

3.2. Applications of AI in Reproductive Health

In Europe, pregnancy rates and live birth rates for all treatment options vary widely between countries. Overall success rates decline sharply to less than 20% when women are above 38 years of age. In other words: the expectations of embryo transfer reduce drastically. This fact, together with the emotional and mental stress that infertility creates, explains the increased attention to complementary treatments such as acupuncture, or yoga. Therefore, it can be assumed that assisted reproductive medicine (ART) could potentially be improved in several areas. Currently, the understanding of the molecular heterogeneity underlying diseases and the therapeutic response is generally lacking. Furthermore, there is a poor prediction, prior to the actual onset of symptoms, of the development of various diseases, neither are there the appropriate personalized medical intervention strategies tailored to the requirements of each patient. Now that these systems are coming into more general use, it is hoped that the automatic classification of, e.g., sperm, embryos and oocytes will be possible, thereby increasing the success rates of in-vitro fertilization (IVF).

In order to understand the work undertaken, it is essential to clarify that the definition of artificial intelligence (AI) in this text is using complex algorithms to imitate logical thinking and cognitive functions. Machine learning (ML) is a particularly successful AI application. ML is a mathematical approach that is based on identifying patterns between variables in large datasets. Therefore, ML can find correlations between variables that were previously unknown. In this way, new hypotheses could be generated, thus different fields may be

pioneered. It is also important to clarify that deep learning (DL) is a variant of ML. DL is an algorithm that attempts to imitate the functions of the human brain. This is done using different levels of artificial neural networks to generate automatic predictions based on proprietary training datasets. The results of this research show a novel and promising clinical approach in the field of reproductive medicine in which decisions for patients struggling with infertility may be made based on an analysis of a variety of medical data. Fertility experts specializing in reproductive medicine can use ML models developed to help them identify the most suitable treatments for persons with a desire to procreate, but still without success. The subjects of these analyses are of a physical nature, for example, the detection of maternal inflammation (subsequently leading to obstetric complications) or the analysis of preimplantation embryo metabolism. In both cases, advanced microarray techniques are used. On the other hand, reproductive medicine specialists may simply want a prediction.

Equ 2: Model Uncertainty (Bayesian Inference)

Where:

$$P(\theta|\mathbf{X}) = \frac{P(\mathbf{X}|\theta)P(\theta)}{P(\mathbf{X})}$$

- θ represents the genetic parameters.
- \mathbf{X} is the observed genomic data.
- $P(\mathbf{X}|\theta)$ is the likelihood of observing data
- $P(\theta)$ is the prior distribution.
- $P(\mathbf{X})$ is the marginal likelihood.

4.

Generative AI Frameworks

Artificial Intelligence (AI) has continuously been driving a revolutionary transformation in numerous industries, healthcare being the most notable example considering significant improvements in both efficiency and effectiveness. Particularly, generative AI presents an unparalleled ability to generate human-like outputs across an extensive range of formats, such as text, images, audio, video, and code. Generative AI algorithms have evolved rapidly in recent times, allowing them to generate highly realistic and complex samples that closely mimic authentic human creation. The significant implications of this technology for healthcare are self-evident. Yet, no framework was devised regarding the practical implementation approaches for medically oriented generative AI and the associated ethical considerations.

A systematically structured, ethically compliant procedural synthesis for the practical application of generative AI within the precision carrier screening landscape is presented, with the focus lying on reproductive health. Due to the more straightforward identification process and a well-established body of literature, parents at risk of specific genetic conditions will be identified as the prototypical example. Precursor necessity considerations are then set forth, together with the definition of the problem, the proposed generative AI premise, the prototypical relationships, the structure of the generative AI database, and the elaboration of the central hypothesis. The subsequent stage anticipates the abstract formulation of the generative AI methodology, outlining in greater depth the objectives and methodologies.

The benchmark cohort strategy is then delineated, together with conformity considerations introducing real-world practical constraints. Furthermore, the potential implementation, benefits, and drawbacks of generative AI heightened to methodize and perpetrate illegal or unethical conduct are then comprehensively discussed. Finally, the expected societal impacts,

including prospects and countermeasures to potential public concerns, are thoroughly addressed. The application of carrier screening ultimately showcases the potential of generative AI to purvey personalized, multifaceted, and up-to-date information to consumers and their medical practitioners.




Fig 4: Generative AI Frameworks and Tools

4.1. Definition and Types

Here, the main possibilities offered in this study are introduced, followed by a summary and key findings of each study. With the raw input data tokens, a five times repeated five-fold ensemble cross-validation generator with 774M could be fitted in 31 hours. The per-model average F1 scores were 0.5739 for carrier screening indication type, 0.6022 for carrier screening result content, and 0.5817 for pregnancy conception method content. Random sampling and MPPT predicting examples could be used to further apply this generator to a practical application. The benchmarking analysis of representative space models and empirical optimal configurations for the BPE encoding parameter of mBART tokenizer is performed, suggesting that a wider encoding parameter should be used for English tokenizer and translation applications.

4.2. Key Components and Technologies

With the advent of carrier screening (CS) for expanded marker panels, each individual is at risk for a multitude of conditions, thereby complicating counseling. As illustrated in Figure 1, a comprehensive approach to CS algorithm is discussed that includes genome-wide worst-case zygotic mutational load calculation (ACMG incidentalome), as well as the scenario evaluation of early spontaneous dizygotic biovular twinning (isogonal polyzygotic, GO(g)) driven by genotyping deficits. The exact distribution of the worst-case ACMG clinical actionability criterion catalog has been developed for GO(2)Z, GO(3)Z, and GO(4)Z as a variety of normal (daro) development scenarios (DSmin). AP-SSC results are further linked to twin birth statistics. The outlooks of developmental reproductive competence screening (DRCS) strategy are transitively linked. An approach for a zygote to have the worst-case zygotic genome mutational spectrum of the CSAACMG incidentalome is discussed. In parallel, to fill 100% basis, the scenario of early dl2b spontaneous dizygotic biovular twinning is analyzed, with little GIRoleczki (GOv) model emphasizing GO(g) with genotyping and phasing bioerror rates; however, metrics are general for other twin types. On these premises, a set of combinatorial calculable scenario development requirements (DSmin) is developed. The worst-case zygotic mutational load ACMG incidentalome is directly tabulated for all sequenced 2SNPcs (CS) and regards ipCS sets for each DSmin. From huge, prohibitively extensive genetic combinatorial perspectives, it is found that DRCS will not provide relevant results for normal development (Daro) scenarios. Criminally and clinical insight concerns are discussed. Further, in GO(3)Z, tcCS is supported by development of minimized Daro scenarios (DSmin) that enforce CS numbers in terms of spCS. In GO(4)Z, twin birth statistics, CPCr, and tCSdCM expectations are addressed as a function of GIRolecki modeling and ML approaches.

5. Implementation of Generative AI in Precision Carrier Screening

Despite the rise in popularity of generative AI in natural language processing tasks, usage in clinical diagnostics is much rarer thus far. So far, it has generally been implemented with task-specific models outside the clinician workflow, such as in predictive writing tools or patient-facing conversation systems. But this work argues that a new class of large language models (LLMs) can be valuable when implemented directly in electronic health record (EHR) systems. These models use scales of training data, model size, and subsequent performance that push the capabilities of earlier task-specific models. Unlike other technology, these large models can provide generative predictions on a wide variety of input data, both clinical and otherwise, in an unbroken narrative freeform. In parallel, both the EHR landscape and legal environment are evolving in favor of generative AI. A new generation of EHRs that are cloud-based and allow native custom programming are on the horizon, allowing the integration of large language models through API systems. To help encourage implementation, a concise overview of the existing use-cases and recent trends in generative AI is provided. To guide EHR vendors, a framework for evaluating generative AI and assessing relative merits is included.




Fig 5: AI Revolutionizes Precision Medicine

5.1. Data Collection and Preprocessing

Electronic Health Records (EHRs) of 54,664 females aged 18-45 between 2011 and 2017 have been analyzed to develop a highly efficient and scalable method for improved cascade carrier screening (CCS;). This vast sample of a single healthcare provider, staging more than one million consultations/year, is representative of the UK maternal care, and permits to suggest carrier-status feedback for up to 22,671 couples. CCS data on 2,147 carrier-couples for 96 SF conditions were collected, and a control group of 2,147 couples was established. CSV records containing all encounters over the 7-year span were exported, and queries were coded to extract medically relevant terms, along with demographics: procedure-code (DNA tests referring to CCS providing carrier status); diagnosis-code (medical geneticist referrals); and pre-specified free-text columns of user-interacted fields (family history of genetic conditions). Data-cleaning algorithms to deal with the large typology of terms and acronyms in the clinical routine in relation to prior meta-cohort development were applied. The pre-processed data, including carrier status reporting, was used to devise a scalable approach, focusing on the most prevalent conditions compatible with an automatic cascade screen report in the common GenIE format. A public version of the commissioned algorithm, including the SF-ENA interface, considering over 1,200 exact match terms (F-score = 0.81), and 0.7M morphological families (F-score = 0.92), was developed, facilitating comparable analyses in any EHR platform. At least 15.43%

of the queried couples are revealed to be at risk of having missed the opportunity of carrier screening (CS) intervention. A total of 262 carrier couples have been matched, as predicted by the model, and could eventually benefit from a complementary approach to current CS provision. Most of these couples (68.7%), in line with the updated guidelines recommendations, did not undertake pre-conceptional CS referral by medical genetics team. Pregnant women interaction with the medical genetics team is not focused on CS assessment but mainly on NIPD-related matters. Only 1.1% of the matched carrier couples undergo DNA tests for carrier status through a core approach with entry criteria based on the appointment cohort that prioritize screenings for the most prevalent conditions on the patient's ethnicity. All these cases report negative carrier results, despite 80.9% of the requests having been coded following guidelines-multi-referral settings recommendation. Therefore, a substantially more timely and focused intervention is suggested by the query (family history of the same genetic condition shared by the couple), eventually leading in a two-ace investigation to a PGD indication.

5.2. Model Development and Training

The Classification of Ploidy Status on Preimplantation Embryos using Deep Learning. An IdeaPaper on the Impact of AI in the Field of Precision Carrier Screening and Reproductive Health and IoT Data Integration.

Carrier screening programs are crucial to identify common serious Mendelian genetic disorders in reproductive-aged couples before they conceive. However, the majority of people at risk do not get screened due to various reasons, such as financial hardship and lack of awareness. Recently, generative AI frameworks are proposed to generate patient-specific carrier screening libraries with minimal and invisible DNA barcodes for maximum privacy assurance, thereby enabling mass-scale population-wide carrier screening via solely machine vision-assisted sequencing, which could transform genetic testing in the arena of reproductive health .

Machine learning is integral to biology as it is used in numerous genome or transcriptome analyses, mathematical modeling of cellular processes, and computer vision applied to the study of cell and tissue structure. Computational models trained on these datasets can predict observations for new input, experiment with new hypotheses, and interpret results to generate insights that would otherwise be hard to gain. However, the computing setup, knowledge, and time necessary to train useful models from scratch may not be available to traditional bench biologists, so frameworks to build on existing tools would be incredibly valuable. User-friendly pipelines to transform microscopy images into biological measurements are still lacking while components of such methodologies may be already present. Here a framework to facilitate the machine learning model development process for any that have microscopy datasets to analyze will be detailed. So far as it is seen, the package goes far from the typical bioinformatics tools as it is specifically designed for use with images from Olympus scanning laser confocal microscopes and includes multiple preprocessing steps and feature sets tailored to such images.

Equ 3: Error in Variant Prediction

$$\text{Error}(\hat{y}, y) = \sum_{i=1}^N |\hat{y}_i - y_i|$$

Where:

- \hat{y}_i is the predicted value for genetic variant i .
- y_i is the true value for genetic variant i .

6.

Challenges and Ethical Considerations

One of the major reasons why carrier screening has not been implemented as part of prenatal care to the same extent as other forms of screening has been difficulties with knowledge transfer between geneticists and obstetricians. A further obstacle has been the recency and complexity of genetic knowledge, compounded by differing professional interests and norms among medical experts. Rapid developments in molecular genetics now make it possible to screen for hundreds and even thousands of diseases simultaneously. This has produced both new possibilities and new challenges, including the need for interdisciplinary cooperation to interpret and develop guidelines for the application of complex genetic technologies. However, routine genetic testing in the form of carrier screening is typically focused on only a small portion of genetic conditions caused by single gene mutations. Since these are typically rare, the panel of conditions screened can be as small as a dozen or so. While some conditions are more prevalent in certain population groups due to the founder effect, such as cystic fibrosis carrier screening for individuals of European descent, most conditions are pan-ethnic. Unfortunately, many individuals do not know their full ancestry, or their ancestry may be too mixed for these methods to be effective. Implementing broader screening, including conditions that are rare in the general population, is even more difficult. This is where the GenerativeAI testing framework comes in. It can be integrated into the current standard procedure, reduces costs, and has the ability to sequence all coding mutations in one go. Despite the possibility for extensive sequencing, developing guidelines and models for which mutations to include in the testing panels can also be used to reduce costs.

6.1. Data Privacy and Security

Every person is meant to have a unique genetic code, a tool that can re-identify him/her. However, the information about this uniqueness is largely untapped. In this paper, it is shown that genetic data, other than just its sequence, can be utilized for re-identification purposes. To demonstrate this, a setting taken from the de-identification domain used to evaluate the effectiveness of methods designed to protect information about the patients is considered.




Fig : Category knowledge about generative AI

The effectiveness of data de-identification methods is evaluated by attaching, at the time of release of patient information, a level of protection and measuring the re-identification success rate. It is shown that the genetic sequence released together with just age and fingerprints is enough to uniquely re-identify 12% of the U.S. Caucasian. Although such a setting is considered, the approach is not genome specific. The findings demonstrate that genetic data is liable to re-identification attacks. It is suggested a number of guidelines that in part are motivated by the presented results, but apply more generally to the field of patient privacy and security. In particular, newly released sequence data should be, whenever possible, matched solely against those sequences that provided consent to share their data. An explicit demonstration is given that this standard de-identification technique, which removes a number of identifiers present in HIPAA, does not adequately protect genetic information. Also presented is an alternative, k-anonymity based approach to de-identification and disclose

sequences that are protected by it. In the field of bioinformatics, the released biologically important discoveries may be the first step to protect sequence information.

6.2. Bias and Fairness in AI Algorithms

The healthcare field is in the midst of a rapid transformation and the increasing use of Artificial Intelligence (AI) is a major driver. Many organizations are currently using AI to analyze high-dimensional data and make predictions about health outcomes. This has led to a large increase in performance and has made it worthwhile to start using predictive techniques in a wider array of health applications. There are several reasons why AI is particularly promising for the health sector: the increased availability of digital data and computational resources; the development of more powerful machine-learning algorithms; and the ability of AI to tackle complex problems that have traditionally been less tractable to statistical analyses. There are already hundreds of published articles that set out the many ways in which AI can potentially transform healthcare, from predicting hospitalizations to understanding the biology of diseases. Some have argued that AI could enhance the quality, access, and efficiency of care, potentially saving billions of dollars. Patient involvement in decision-making, interactions with health professionals, patient safety, diagnostic accuracy, health service planning, and administrative efficiency are all mentioned as potential outlets for the positive effect of AI. However, there is a caveat to the massive adoption of these techniques that is beginning to be noticed. As with any new technology, there are risks that need to be addressed to optimize safety and effectiveness. In the case of health, there are growing fears that, rather than advancing health equity goals, the increased use of AI could make an already unfair system even more unjust. The use of AI in this area is increasingly being raised as an issue, and the algorithm's potential role in exacerbating health disparities is being questioned. Previous work has attempted to illustrate the numerous ways in which algorithmic clinical prediction may unintentionally increase health disparities.

7. Future Directions and Conclusion

Carrier screening is a type of genetic test which can calculate a couple's risk of having a child with autosomal recessive or X-linked conditions. When the potential parents are related, there is a higher risk of having an affected child due to the high possibility of carrying the same recessive disease variant. For this reason, consanguineous couples, who share a bloodline, are strongly advised to undergo carrier testing to estimate the specific chance of conceiving an affected baby. Although consanguinity is more common in some populations than others, its prevalence is globally estimated at 0.1%, totaling a relevant number of couples seeking to have children.

Carrier screening can be performed before pregnancy planning, so that a couple can get all the information about their reproductive choices and avoid the pain of losing multiple ongoing pregnancies or proceeding with the termination of a much-wanted baby.

It is estimated the probability of consanguineous couples to be carriers of a variant for at least one autosomal recessive condition close to 100% while the same is true for X-linked conditions in more than 50% of cases. A crucial task is to accurately inform them about their actual chance of having a baby with a specific disorder to allow them to make conscious choices about their reproductive opportunities. CarrierSequencing is a comprehensive, affordable, and instrumental carrier screening framework purposely implemented to be optimized for the follow up layman genetic counseling.

7.1. Emerging Trends and Innovations

Despite numerous studies pointing out the limited capacity of the human eye in accurately evaluating the morphologic quality of embryos, morphokinetic (time-lapse) observation of their development confirmed to a certain extent that there is a relationship between morphokinetics and the genetic composition of embryos. Yet, the aforementioned method does not enable full assessment of the genetic complement of the embryo, and about 90% of morphologic abnormalities in human embryos are composed of euploid cells. Consequently, only PGT following the genetic quality of the embryos and providing additional criteria of evaluation of clinical competence of embryos, especially in women of advanced reproductive age with poor ovarian response, male factor infertility, or multiple IVF history, seems to bring forward an essential enhancement in treatment prognosis. This does not address, however, a more general picture of personal reproductive competence. Efforts have been made to associate PGT results with other properties of the embryo able to predict its implantation potential, primarily concerning aneuploidy. Recently, users were also proposed assessing the number of mitochondria in the same biopsying sample from which the genetic analysis is carried out, in PGT association between mtDNA copy number and aneuploidy in PGT from an infertile couple. An encouraging association was found, the possible sources of which were stressed. However, the tested samples were not numerous and the control was the untransferred control sample, showing limited value since it cannot assess embryos' reproductive competence. Further analysis is needed, focusing on samples diagnosed as normal embryos. Simultaneously, more reliable evaluation methods need to be tested. In addition, data are provided from the validation of the two depletion protocols. Outcomes show that a simple Plasma may overly deplete the sample and significantly interfere with the PGT results. Alternatively, a new approach used in a biopsy well can remove DNA molecules within the lower range of the length of mitochondrial DNA ensuring the presence of suitable long DNA for PGT analysis. This protocol seems to be effective and suitable for future analysis. The present achievements may lead to a wider application of control with a powerful methodology capable of monitoring reproductive competence at a pre-implantation stage. More comprehensive biopsy always provides greater confidence in the test results. The mini-proof of a cutting-edge work is capable of pinpointing this spin underlining the enhancement of the initial observation made in ref. Early application of the current system can provide a broad vision of PGT products and serve as benchmarking to improve skills. The overall effort will undoubtedly improve understanding of the Rd and the embryo, since this just improves PGT performance, supporting the release of prejudiced conclusions on specific aspects, discussed to help a broader understanding. The re-edited text was taken into account.

7.2. Summary of Findings

The findings are organized into three broad categories: whether genome sequencing with carrier testing should be used in preconception or prenatal care; decisions around categorizing and disclosing carrier testing findings; and considerations about how to manage the information that comes from the carrier findings framework.

Considering whether genome sequencing should be used with carrier testing in preconception care or made available during prenatal care is the most broadly applicable finding. These findings indicate that genome sequencing as a carrier testing strategy could identify one or more X-linked or autosomal recessive conditions that could be disclosed during preconception or prenatal counseling. To educate and respect patient preferences, a carrier findings framework that helps clinicians and patients understand the possible range of findings is needed. Various frameworks and tools have been developed that could be adapted for use with a carrier testing result. To illustrate the kinds of additional findings that might come from a genome sequencing approach, a de identified sample case is presented. Of particular note,

findings are predominantly considered for adult onset conditions. This is likely due to the fact that most carriers of severe, childhood onset conditions have an affected child. Although discussed as distinct from carrier testing findings, the identification of a 2-year-old carrier is arguably an indirect or familial risk finding.

This study provides a more nuanced view of the types of results that could be returned so that patients can receive appropriate counseling. Once a uniform system for categorizing and disclosing carrier status is in place, the decision to disclose carrier results alone or carrier results plus additional findings can be made. Examples are provided of how the framework could be used during preconception carrier testing or in prenatal care, as well as considering undesirable outcomes.

8. References

- [1] Vaka, D. K. (2024). Enhancing Supplier Relationships: Critical Factors in Procurement Supplier Selection. In *Journal of Artificial Intelligence, Machine Learning and Data Science* (Vol. 2, Issue 1, pp. 229–233). United Research Forum. <https://doi.org/10.51219/jaimld/dilip-kumar-vaka/74>
- [2] Ravi Kumar Vankayalapati , Chandrashekar Pandugula , Venkata Krishna Azith Teja Ganti , Ghatoth Mishra. (2022). AI-Powered Self-Healing Cloud Infrastructures: A Paradigm For Autonomous Fault Recovery. *Migration Letters*, 19(6), 1173–1187. Retrieved from <https://migrationletters.com/index.php/ml/article/view/11498>
- [3] Syed, S. (2024). Enhancing School Bus Engine Performance: Predictive Maintenance and Analytics for Sustainable Fleet Operations. *Library Progress International*, 44(3), 17765-17775.
- [4] Nampalli, R. C. R. (2024). AI-Enabled Rail Electrification and Sustainability: Optimizing Energy Usage with Deep Learning Models. *Letters in High Energy Physics*.
- [5] Lekkala, S. (2024). Next-Gen Firewalls: Enhancing Cloud Security with Generative AI. In *Journal of Artificial Intelligence & Cloud Computing* (Vol. 3, Issue 4, pp. 1–9). Scientific Research and Community Ltd. [https://doi.org/10.47363/jaicc/2024\(3\)404](https://doi.org/10.47363/jaicc/2024(3)404)
- [6] Manikanth Sarisa , Gagan Kumar Patra , Chandrababu Kuraku , Siddharth Konkimalla , Venkata Nagesh Boddapati. (2024). Stock Market Prediction Through AI: Analyzing Market Trends With Big Data Integration . *Migration Letters*, 21(4), 1846–1859. Retrieved from <https://migrationletters.com/index.php/ml/article/view/11245>
- [7] Vaka, D. K. (2024). From Complexity to Simplicity: AI's Route Optimization in Supply Chain Management. In *Journal of Artificial Intelligence, Machine Learning and Data Science* (Vol. 2, Issue 1, pp. 386–389). United Research Forum. <https://doi.org/10.51219/jaimld/dilip-kumar-vaka/100>
- [8] Tulasi Naga Subhash Polineni , Kiran Kumar Maguluri , Zakera Yasmeen , Andrew Edward. (2022). AI-Driven Insights Into End-Of-Life Decision-Making: Ethical, Legal, And Clinical Perspectives On Leveraging Machine Learning To

Improve Patient Autonomy And Palliative Care Outcomes. *Migration Letters*, 19(6), 1159–1172. Retrieved from <https://migrationletters.com/index.php/ml/article/view/11497>

[9] Shakir Syed. (2024). Planet 2050 and the Future of Manufacturing: Data-Driven Approaches to Sustainable Production in Large Vehicle Manufacturing Plants. *Journal of Computational Analysis and Applications (JoCAAA)*, 33(08), 799–808. Retrieved from <https://www.eudoxuspress.com/index.php/pub/article/view/1453>

[10] Nampalli, R. C. R., & Adusupalli, B. (2024). Using Machine Learning for Predictive Freight Demand and Route Optimization in Road and Rail Logistics. *Library Progress International*, 44(3), 17754-17764.

[11] Ramanakar Reddy Danda (2024) Financial Services in the Capital Goods Sector: Analyzing Financing Solutions for Equipment Acquisition. *Library Progress International*, 44(3), 25066-25075

[12] Chandrababu Kuraku, Shravan Kumar Rajaram, Hemanth Kumar Gollangi, Venkata Nagesh Boddapati, Gagan Kumar Patra (2024). Advanced Encryption Techniques in Biometric Payment Systems: A Big Data and AI Perspective. *Library Progress International*, 44(3), 2447-2458.

[13] Vaka, D. K. (2024). Integrating Inventory Management and Distribution: A Holistic Supply Chain Strategy. In the *International Journal of Managing Value and Supply Chains* (Vol. 15, Issue 2, pp. 13–23). Academy and Industry Research Collaboration Center (AIRCC). <https://doi.org/10.5121/ijmvsc.2024.15202>

[14] Vankayalapati, R. K., Sondinti, L. R., Kalisetty, S., & Valiki, S. (2023). Unifying Edge and Cloud Computing: A Framework for Distributed AI and Real-Time Processing. In *Journal for ReAttach Therapy and Developmental Diversities*. Green Publication. [https://doi.org/10.53555/jrtdd.v6i9s\(2\).3348](https://doi.org/10.53555/jrtdd.v6i9s(2).3348)

[15] Syed, S. (2024). Sustainable Manufacturing Practices for Zero-Emission Vehicles: Analyzing the Role of Predictive Analytics in Achieving Carbon Neutrality. *Utilitas Mathematica*, 121, 333-351.

[16] Nampalli, R. C. R., & Adusupalli, B. (2024). AI-Driven Neural Networks for Real-Time Passenger Flow Optimization in High-Speed Rail Networks. *Nanotechnology Perceptions*, 334-348.

[17] Ramanakar Reddy Danda, Valiki Dileep,(2024) Leveraging AI and Machine Learning for Enhanced Preventive Care and Chronic Disease Management in Health Insurance Plans. *Frontiers in Health Informatics*, 13 (3), 6878-6891

[18] Sanjay Ramdas Bauskar, Chandrakanth Rao Madhavaram, Eswar Prasad Galla, Janardhana Rao Sunkara, Hemanth Kumar Gollangi (2024) AI-Driven Phishing Email Detection: Leveraging Big Data Analytics for Enhanced Cybersecurity. *Library Progress International*, 44(3), 7211-7224.

- [19] Dilip Kumar Vaka. (2019). Cloud-Driven Excellence: A Comprehensive Evaluation of SAP S/4HANA ERP. *Journal of Scientific and Engineering Research*. <https://doi.org/10.5281/ZENODO.11219959>
- [20] Maguluri, K. K., Pandugula, C., Kalisetty, S., & Mallesham, G. (2022). Advancing Pain Medicine with AI and Neural Networks: Predictive Analytics and Personalized Treatment Plans for Chronic and Acute Pain Managements. *Journal of Artificial Intelligence and Big Data*, 2(1), 112–126. Retrieved from <https://www.scipublications.com/journal/index.php/jaibd/article/view/1201>
- [21] Syed, S. (2024). Transforming Manufacturing Plants for Heavy Vehicles: How Data Analytics Supports Planet 2050's Sustainable Vision. *Nanotechnology Perceptions*, 20(6), 10-62441.
- [22] Nampalli, R. C. R. (2024). Leveraging AI and Deep Learning for Predictive Rail Infrastructure Maintenance: Enhancing Safety and Reducing Downtime. *International Journal of Engineering and Computer Science*, 12(12), 26014–26027. <https://doi.org/10.18535/ijecs/v12i12.4805>
- [23] Danda, R. R., Nishanth, A., Yasmeen, Z., & Kumar, K. (2024). AI and Deep Learning Techniques for Health Plan Satisfaction Analysis and Utilization Patterns in Group Policies. *International Journal of Medical Toxicology & Legal Medicine*, 27(2).
- [24] Data Engineering Solutions: The Impact of AI and ML on ERP Systems and Supply Chain Management. (2024). In *Nanotechnology Perceptions* (Vol. 20, Issue S9). Rotherham Press. <https://doi.org/10.62441/nano-ntp.v20is9.47>
- [25] Vaka, D. K. (2020). Navigating Uncertainty: The Power of 'Just in Time SAP for Supply Chain Dynamics. *Journal of Technological Innovations*, 1(2).
- [26] Danda, R. R. (2024). Generative AI in Designing Family Health Plans: Balancing Personalized Coverage and Affordability. *Utilitas Mathematica*, 121, 316-332.
- [27] Pandugula, C., Kalisetty, S., & Polineni, T. N. S. (2024). Omni-channel Retail: Leveraging Machine Learning for Personalized Customer Experiences and Transaction Optimization. *Utilitas Mathematica*, 121, 389-401.
- [28] Syed, S. (2023). Shaping The Future Of Large-Scale Vehicle Manufacturing: Planet 2050 Initiatives And The Role Of Predictive Analytics. *Nanotechnology Perceptions*, 19(3), 103-116.
- [29] Nampalli, R. C. R. (2023). Moderlizing AI Applications In Ticketing And Reservation Systems: Revolutionizing Passenger Transport Services. In *Journal for ReAttach Therapy and Developmental Diversities*. Green Publication. [https://doi.org/10.53555/jrtd.v6i10s\(2\).3280](https://doi.org/10.53555/jrtd.v6i10s(2).3280)
- [30] Malviya, R. K., Danda, R. R., Maguluri, K. K., & Kumar, B. V. (2024). Neuromorphic Computing: Advancing Energy-Efficient AI Systems through Brain-

Inspired Architectures. Nanotechnology Perceptions, 1548-1564.

[31] Patra, G. K., Kuraku, C., Konkimalla, S., Boddapati, V. N., Sarisa, M. and Reddy, M. S. (2024) An Analysis and Prediction of Health Insurance Costs Using Machine Learning-Based Regressor Techniques . Journal of Data Analysis and Information Processing, 12, 581-596. doi: 10.4236/jdaip.2024.124031.

[32] Danda, R. R. (2024). Generative AI for Enhanced Engagement in Digital Wellness Programs: A Predictive Approach to Health Outcomes. Journal of Computational Analysis and Applications (JoCAAA), 33(08), 788-798.

[33] Kalisetty, S., Pandugula, C., & Mallesham, G. (2023). Leveraging Artificial Intelligence to Enhance Supply Chain Resilience: A Study of Predictive Analytics and Risk Mitigation Strategies. Journal of Artificial Intelligence and Big Data, 3(1), 29–45. Retrieved from <https://www.scipublications.com/journal/index.php/jaibd/article/view/1202>

[34] Ramanakar Reddy Danda, Z. Y., Mandala, G., & Maguluri, K. K. Smart Medicine: The Role of Artificial Intelligence and Machine Learning in Next-Generation Healthcare Innovation.

[35] Madhavaram, C. R., Sunkara, J. R., Kuraku, C., Galla, E. P., & Gollangi, H. K. (2024). The Future of Automotive Manufacturing: Integrating AI, ML, and Generative AI for Next-Gen Automatic Cars. In IMRJR (Vol. 1, Issue 1). Tejass Publishers. <https://doi.org/10.17148/imrjr.2024.010103>

[36] Danda, R. R. (2024). Using AI-Powered Analysis for Optimizing Prescription Drug Plans among Seniors: Trends and Future Directions. Nanotechnology Perceptions, 2644-2661.

[37] Sondinti, L. R. K., Kalisetty, S., Polineni, T. N. S., & abhireddy, N. (2023). Towards Quantum-Enhanced Cloud Platforms: Bridging Classical and Quantum Computing for Future Workloads. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. [https://doi.org/10.53555/jrtdd.v6i10s\(2\).3347](https://doi.org/10.53555/jrtdd.v6i10s(2).3347)

[38] Danda, R. R. (2024). The Role of Machine Learning Algorithms in Enhancing Wellness Programs and Reducing Healthcare Costs. Utilitas Mathematica, 121, 352-364.

[39] Bauskar, S. R., Madhavaram, C. R., Galla, E. P., Sunkara, J. R., Gollangi, H. K. and Rajaram, S. K. (2024) Predictive Analytics for Project Risk Management Using Machine Learning. Journal of Data Analysis and Information Processing, 12, 566-580. doi: 10.4236/jdaip.2024.124030.

[40] Maguluri, K. K., Pandugula, C., & Yasmeen, Z. (2024). Neural Network Approaches for Real-Time Detection of Cardiovascular Abnormalities.

[41] Reddy, R. (2023). Predictive Health Insights: Ai And Ml's Frontier In Disease Prevention And Patient Management. Available at SSRN 5038240.

- [42] Korada, L. (2024). Use Confidential Computing to Secure Your Critical Services in Cloud. *Machine Intelligence Research*, 18(2), 290-307.
- [43] Sunkara, J. R., Bauskar, S. R., Madhavaram, C. R., Galla, E. P., & Gollangi, H. K. (2023). Optimizing Cloud Computing Performance with Advanced DBMS Techniques: A Comparative Study. In *Journal for ReAttach Therapy and Developmental Diversities*. Green Publication. [https://doi.org/10.53555/jrtdd.v6i10s\(2\).3206](https://doi.org/10.53555/jrtdd.v6i10s(2).3206)
- [44] Danda, R. R., Nampalli, R. C. R., Sondinti, L. R. K., Vankayalapati, R. K., Syed, S., Maguluri, K. K., & Yasmeen, Z. (2024). Harnessing Big Data and AI in Cloud-Powered Financial Decision-Making for Automotive and Healthcare Industries: A Comparative Analysis of Risk Management and Profit Optimization.
- [45] Eswar Prasad G, Hemanth Kumar G, Venkata Nagesh B, Manikanth S, Kiran P, et al. (2023) Enhancing Performance of Financial Fraud Detection Through Machine Learning Model. *J Contemp Edu Theo Artific Intel: JCETAI*-101.
- [46] Laxminarayana Korada, V. K. S., & Somepalli, S. Finding the Right Data Analytics Platform for Your Enterprise.
- [47] Polineni, T. N. S., abhireddy, N., & Yasmeen, Z. (2023). AI-Powered Predictive Systems for Managing Epidemic Spread in High-Density Populations. In *Journal for ReAttach Therapy and Developmental Diversities*. Green Publication. [https://doi.org/10.53555/jrtdd.v6i10s\(2\).3374](https://doi.org/10.53555/jrtdd.v6i10s(2).3374)
- [48] Sondinti, L. R. K., & Yasmeen, Z. (2022). Analyzing Behavioral Trends in Credit Card Fraud Patterns: Leveraging Federated Learning and Privacy-Preserving Artificial Intelligence Frameworks.
- [49] Siddharth K, Gagan Kumar P, Chandrababu K, Janardhana Rao S, Sanjay Ramdas B, et al. (2023) A Comparative Analysis of Network Intrusion Detection Using Different Machine Learning Techniques. *J Contemp Edu Theo Artific Intel: JCETAI*-102.
- [50] Korada, L. (2024). GitHub Copilot: The Disrupting AI Companion Transforming the Developer Role and Application Lifecycle Management. *Journal of Artificial Intelligence & Cloud Computing*. SRC/JAICC-365. DOI: [doi.org/10.47363/JAICC/2024\(3\),348,2-4](https://doi.org/10.47363/JAICC/2024(3),348,2-4).
- [51] Subhash Polineni, T. N., Pandugula, C., & Azith Teja Ganti, V. K. (2022). AI-Driven Automation in Monitoring Post-Operative Complications Across Health Systems. *Global Journal of Medical Case Reports*, 2(1), 1225. Retrieved from <https://www.scipublications.com/journal/index.php/gjmcr/article/view/1225>
- [52] Danda, R. R. Digital Transformation In Agriculture: The Role Of Precision Farming Technologies.
- [53] Janardhana Rao Sunkara, Sanjay Ramdas Bauskar, Chandrakanth Rao

Madhavaram, Eswar Prasad Galla, Hemanth Kumar Gollangi, et al. (2023) An Evaluation of Medical Image Analysis Using Image Segmentation and Deep Learning Techniques. *Journal of Artificial Intelligence & Cloud Computing*. SRC/JAICC-407.DOI: doi.org/10.47363/JAICC/2023(2)388

[54] Korada, L. (2024). Data Poisoning-What Is It and How It Is Being Addressed by the Leading Gen AI Providers. *European Journal of Advances in Engineering and Technology*, 11(5), 105-109.

[55] Kothapalli Sondinti, L. R., & Yasmeen, Z. (2022). Analyzing Behavioral Trends in Credit Card Fraud Patterns: Leveraging Federated Learning and Privacy-Preserving Artificial Intelligence Frameworks. *Universal Journal of Business and Management*, 2(1), 1224. Retrieved from <https://www.scipublications.com/journal/index.php/ujbm/article/view/1224>

[56] Chitta, S., Yandrapalli, V. K., & Sharma, S. (2024, June). Deep Learning for Precision Agriculture: Evaluating CNNs and Vision Transformers in Rice Disease Classification. In 2024 OPJU International Technology Conference (OTCON) on Smart Computing for Innovation and Advancement in Industry 4.0 (pp. 1-6). IEEE.

[57] Gagan Kumar Patra, Chandrababu Kuraku, Siddharth Konkimalla, Venkata Nagesh Boddapati, Manikanth Sarisa, et al. (2023) Sentiment Analysis of Customer Product Review Based on Machine Learning Techniques in E-Commerce. *Journal of Artificial Intelligence & Cloud Computing*. SRC/JAICC-408.DOI: doi.org/10.47363/JAICC/2023(2)38

[58] Korada, L. Role of Generative AI in the Digital Twin Landscape and How It Accelerates Adoption. *J Artif Intell Mach Learn & Data Sci* 2024, 2(1), 902-906.

[59] Kothapalli Sondinti, L. R., & Syed, S. (2021). The Impact of Instant Credit Card Issuance and Personalized Financial Solutions on Enhancing Customer Experience in the Digital Banking Era. *Universal Journal of Finance and Economics*, 1(1), 1223. Retrieved from <https://www.scipublications.com/journal/index.php/ujfe/article/view/1223>

[60] Chitta, S., Yandrapalli, V. K., & Sharma, S. (2024, June). Advancing Histopathological Image Analysis: A Combined EfficientNetB7 and ViT-S16 Model for Precise Breast Cancer Detection. In 2024 OPJU International Technology Conference (OTCON) on Smart Computing for Innovation and Advancement in Industry 4.0 (pp. 1-6). IEEE.

[61] Nagesh Boddapati, V. (2023). AI-Powered Insights: Leveraging Machine Learning And Big Data For Advanced Genomic Research In Healthcare. In *Educational Administration: Theory and Practice* (pp. 2849–2857). Green Publication. <https://doi.org/10.53555/kuey.v29i4.7531>

[62] Pradhan, S., Nimavat, N., Mangrola, N., Singh, S., Lohani, P., Mandala, G., ... & Singh, S. K. (2024). Guarding Our Guardians: Navigating Adverse Reactions in Healthcare Workers Amid Personal Protective Equipment (PPE) Usage During

COVID-19. Cureus, 16(4).

[63] Patra, G. K., Kuraku, C., Konkimalla, S., Boddapati, V. N., & Sarisa, M. (2023). Voice classification in AI: Harnessing machine learning for enhanced speech recognition. *Global Research and Development Journals*, 8(12), 19–26. <https://doi.org/10.70179/grdjev09i110003>

[64] Vankayalapati, R. K., Edward, A., & Yasmeen, Z. (2021). Composable Infrastructure: Towards Dynamic Resource Allocation in Multi-Cloud Environments. *Universal Journal of Computer Sciences and Communications*, 1(1), 1222. Retrieved from <https://www.scipublications.com/journal/index.php/ujcsc/article/view/1222>

[65] Mandala, V., & Mandala, M. S. (2022). ANATOMY OF BIG DATA LAKE HOUSES. *NeuroQuantology*, 20(9), 6413.